For patients with Parkinson's disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist ...

For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist ...

Oral carbidopa-levodopa formulation improves sleep in Parkinson disease, particularly addressing sleep disturbances and ...

This condition currently affects nearly 10 million people, and by 2050, it’s estimated to reach 25.2 million cases.

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Get Instant Summarized Text (Gist) Levodopa, a dopamine-enhancing medication, may improve motivation in depression linked to high inflammation. Individuals with C-reactive protein (CRP) levels ...

Neurological disorders are among the most disabling illnesses all over the world . Alzheimer rsquo;s disease and Parkinson rsquo;s disease are the two top disorders among them .

Parkinson's disease cases are projected to surge by 112% globally by 2050, reaching 25.2 million. Early detection is crucial, ...

More than 2,000 people in Taiwan are diagnosed with Parkinson’s disease each year, but the criteria for receiving treatment ...

Solengepras shows strong potential as an adjunctive therapy for Parkinson’s, offering a novel, well-tolerated option with ...